GLP1R and obesity disorder: These reductions are lower than the effects seen with injectable GLP‐1 receptor agonists such as semaglutide (15%–17% weight loss) and tirzepatide (15%–22% weight loss) but clinically meaningful and comparable to those observed with other oral anti‐obesity agents [14, 29].